Phase 1a First in Human, Time Lagged, Parallel-Group, Single Ascending Dose Study of Tyzivumab in Healthy Adult Volunteers

Trial Profile

Phase 1a First in Human, Time Lagged, Parallel-Group, Single Ascending Dose Study of Tyzivumab in Healthy Adult Volunteers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Feb 2018

At a glance

  • Drugs Tyzivumab (Primary)
  • Indications Zika virus infection
  • Focus Adverse reactions; First in man
  • Sponsors Tychan
  • Most Recent Events

    • 28 Feb 2018 New trial record
    • 07 Feb 2018 According to the Tychan media release, first patient will be dosed on 8th February 2018, following a regulatory authorisation by the Health Sciences Authority, Singapore.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top